Crescent Biopharma, Inc. (CBIO) Stock Forecast & Price Target
Crescent Biopharma, Inc. · NASDAQ
$16.94+0.64 (+3.93%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Crescent Biopharma, Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $22.00 to $35.00, a moderate spread. The average target of $27.67 sits 63% above the current $16.94. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.61 next quarter toward $-2.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Crescent Biopharma, Inc.
As of Jul, 2 of 3 firms rate CBIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.61
Range $-0.67 – $-0.56 · 3 analysts · -56% YoY
Next period, 3 analysts expect Crescent Biopharma, Inc. to earn $-0.61 a share (range $-0.67 – $-0.56), versus $-1.37 a year earlier. Full-year consensus is $-2.49, growing to $-2.98 the year after.
REVENUE · NEXT QUARTER
$357.1K
Range $0 – $2.5M · 3 analysts
Revenue is expected to reach $357.1K (range $0 – $2.5M). Full-year consensus is $2.1M, rising to $5.6M next year.
Top analysts covering Crescent Biopharma, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CBIO.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Hold
No targeton CBIO
Overall win rate
34%
+ Follow
#2
Robert Driscoll
Wedbush · Rank #313
Buy
$27.00+59.4% to target
Overall win rate
30%
+ Follow
#3
Akash Tewari
Jefferies
Buy
$35.00+106.6% to target
Coverage
—
+ Follow
#4
CZ
Charles Zhu
LifeSci Capital
Buy
$28.00+65.3% to target
Coverage
—
+ Follow
#5
Phil Nadeau
TD Cowen
Buy
No targeton CBIO
Coverage
—
+ Follow
CBIO stock forecast FAQ
What is CBIO's average 12-month price target?+
The 2 analysts with a live target average $27.67 for Crescent Biopharma, Inc. over the next 12 months, ranging from a $35.00 high to a $22.00 low.
Is CBIO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CBIO?+
The Street-high target is $35.00 (Guggenheim), and the Street-low is $22.00. The average of all 2 active targets is $27.67.
How many Wall Street analysts cover CBIO?+
3 analysts have an active rating on Crescent Biopharma, Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering CBIO?+
Among analysts who currently cover CBIO, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #165). Their current call is Hold.
What is Crescent Biopharma, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.61 per share (range $-0.67 – $-0.56) across 3 analysts. Full-year EPS is projected at $-2.49, rising to $-2.98 the following year.
How much revenue is Crescent Biopharma, Inc. expected to report next quarter?+
Consensus revenue is $357.1K (range $0 – $2.5M). Full-year revenue is projected at $2.1M, growing to $5.6M next year.
Have analysts been upgrading or downgrading CBIO lately?+
As of Jul, 2 of 3 firms rate CBIO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
